The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials

Table 2 Meta-analysis of clinical symptoms in pre- and post-therapy

Symptom	Time point	Number of studies	Heterogeneity		Odds ratio (OR)	95% CI	P value
Symptom	Time point	Number of studies	I²	P value	Odds ratio (OR)	95% CI	P value
Encephalopathy	Baseline	2	0	0.457	0.65	0.30–1.41	0.278
	End of treatment	2	31.8	0.231	0.40	0.18–0.89	0.025
Gastrointestinal hemorrhage	Baseline	3	0	0.491	0.80	0.19–3.35	0.760
	End of treatment	3	1.9	0.361	0.32	0.07–0.97	0.045
Edema	Baseline	4	0	0.379	1.33	0.58–3.06	0.495
	End of treatment	4	46.6	0.132	0.64	0.27–1.49	0.298
Rash	Baseline	4	0	0.491	1.11	0.22–5.73	0.900
	End of treatment	4	9.2	0.347	0.73	0.26–2.07	0.555
Itching	Baseline	2	0	0.491	0.44	0.06–3.16	0.417
	End of treatment	2	57.2	0.127	0.45	0.08–2.45	0.352

ISSN: 1757-6512